VICTORIAとVICTOR試験の個々の参加者のデータ分析

Faiez Zannad¹, Christopher M O'Connor², Javed Butler³

¹Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, CHRU, Nancy, France.

Lancet (London, England)

|September 2, 2025

まとめ

ベリシガートは,心不全の患者における心血管疾患による死亡と心不全による入院を有意に減少させた. この発見は,選択されたHFrEF患者に対する追加の治療選択肢として, vericiguatを支持する.

科学分野:

心臓病科
薬理学について
臨床試験

背景:

ベリシグアートは,心不全の悪化とエジェクション分数減少 (HFrEF) の治療に承認されています.
VICTOR試験では,HFrEF患者で最近の悪化を評価した.
以前の研究では,高リスクのHFrEF集団における vericiguatの利点が確認されました.

研究の目的:

より広範なHFrEF集団における vericiguatの有効性を評価する.
心血管疾患による死亡と心不全による入院の影響を評価する.
VICTORIAとVICTOR試験の患者レベルのデータをまとめ分析する.

主な方法:

VICTORIAとVICTORの試験から得られたデータを個人レベルで分析した.
最近の悪化を伴うHFrEFを持つ成人の参加者を対象とした.
主なエンドポイントは,心血管疾患による死亡または心不全による入院でした.

主要な成果:

11155人の患者が総合分析に含まれました.
ベリシグアートは,プライマリコンポジットエンドポイントを有意に低下させた (HR 0. 91; p=0. 0088).
心血管疾患による死亡 (HR 0. 89; p=0. 020) と心不全による入院 (HR 0. 92; p=0. 043) の有意な減少が見られた.

結論:

Vericiguatは,HFrEF患者における心不全の入院および心血管疾患による死亡のリスクを効果的に低下させる.
HFrEFでは,臨床的重症度の幅広い範囲にわたる利点があります.
選択されたHFrEF患者にとって,Vericiguatは潜在的に追加的な治療法である.

さらに関連する動画

14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K

10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

903

関連する概念動画

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

505

01:22

Heart Failure Drugs: Diuretics

483

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

483

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

223

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

223

01:22

Heart Failure Drugs: β-Blockers

434

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

434

01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

関連する実験動画